PAHC vs. RYTM, LEGN, ABVX, RNA, CYTK, AXSM, CRSP, NUVL, MRUS, and TGTX
Should you be buying Phibro Animal Health stock or one of its competitors? The main competitors of Phibro Animal Health include Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), Avidity Biosciences (RNA), Cytokinetics (CYTK), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Nuvalent (NUVL), Merus (MRUS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.
Phibro Animal Health vs. Its Competitors
Phibro Animal Health (NASDAQ:PAHC) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.
99.3% of Phibro Animal Health shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 6.1% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Phibro Animal Health had 3 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 5 mentions for Phibro Animal Health and 2 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.87 beat Phibro Animal Health's score of 0.80 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.
Phibro Animal Health has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
Phibro Animal Health has a net margin of 3.73% compared to Rhythm Pharmaceuticals' net margin of -117.13%. Phibro Animal Health's return on equity of 32.14% beat Rhythm Pharmaceuticals' return on equity.
Phibro Animal Health currently has a consensus target price of $28.40, indicating a potential downside of 25.63%. Rhythm Pharmaceuticals has a consensus target price of $106.64, indicating a potential upside of 7.43%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Phibro Animal Health.
Phibro Animal Health has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500.
Summary
Phibro Animal Health beats Rhythm Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Phibro Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PAHC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PAHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phibro Animal Health Competitors List
Related Companies and Tools
This page (NASDAQ:PAHC) was last updated on 10/6/2025 by MarketBeat.com Staff
